AVTE Stock Price, Chart, Stats & News
Aerovate Therapeutics, Inc. (AVTE) is a dividend-paying stock with a current dividend yield of 0.00% as of Apr 28, 2025. It pays $0 per share over the trailing twelve months.
Dividend safety
Dividend coverage looks healthy — AVTE pays out about 0% of earnings.
AVTE chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | 0.05% |
ROA | -36.43% |
ROE | -64.64% |
D/E | 0.00x |
Interest coverage ratio | – |
AVTE valuation
P/E | – |
P/S | – |
P/B | 0.25x |
P/CF | -1.07x |
P/FCF | -0.99x |
P/OCF | -1.07x |
PEG | 0.00x |
EV multiple | -1.46x |
About
Aerovate Therapeutics, Inc. is a clinical-stage biopharmaceutical enterprise focused on innovating therapies to enhance the well-being of patients afflicted with rare cardiopulmonary illnesses across the United States. The company's principal effort involves advancing AV-101, an inhaled dry powder variant of imatinib, which is currently undergoing a Phase 2b/Phase 3 clinical study for the management of pulmonary arterial hypertension. Established in 2018, Aerovate Therapeutics, Inc. maintains its corporate headquarters in Waltham, Massachusetts.
Similar securities
Based on sector and market capitalization
